Literature DB >> 22512985

Keratoplasty for corneal endothelial disease, 2001-2009.

Roni M Shtein1, Duna Raoof-Daneshvar, Hsien-Chang Lin, Alan Sugar, Shahzad I Mian, Bin Nan, Joshua D Stein.   

Abstract

PURPOSE: To determine the rates of keratoplasty for corneal endothelial disease (CED) from 2001 to 2009 in a large managed care network in the United States, factors that affect which patients undergo this procedure and surgical outcomes.
DESIGN: A retrospective review of data from a longitudinal cohort study. PARTICIPANTS: Beneficiaries with CED aged ≥ 40 years who were receiving eye care during 2001 to 2009.
METHODS: Rates of keratoplasty for CED were determined at 6-month intervals from January 2001 to December 2009. The mean number of postoperative visits and rates of severe adverse events in the year after keratoplasty surgery were monitored over the course of the decade. Univariable and multivariable logistic regression were performed to identify sociodemographic and other factors associated with undergoing keratoplasty for CED. MAIN OUTCOME MEASURES: Odds of undergoing keratoplasty with 95% confidence intervals, changes in the number of postoperative visits, and rates of adverse events in the year after keratoplasty.
RESULTS: Of the 38 648 enrollees who met the inclusion criteria, 2187 underwent ≥ 1 keratoplasty surgeries from January 2001 to December 2009. After adjustment for confounding factors, individuals with CED had 47% increased odds of undergoing keratoplasty during 2007-2009 relative to 2001-2006. The mean number of postoperative visits to eyecare providers in the year after keratoplasty declined from 12.6 in 2001-2006 to 10.5 in 2007-2008. There was no difference in the proportion of enrollees who developed adverse events after keratoplasty over time.
CONCLUSIONS: In this analysis of claims data, from 2001 to 2009, a period during which there was an increase in the rate of endothelial keratoplasty, we observed a trend of greater rates of keratoplasty in patients with CED and fewer visits for postoperative care in the later years of the decade compared with the earlier years, along with no change in rates of severe adverse events.
Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22512985      PMCID: PMC3389206          DOI: 10.1016/j.ophtha.2012.01.025

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  18 in total

1.  Akaike's information criterion in generalized estimating equations.

Authors:  W Pan
Journal:  Biometrics       Date:  2001-03       Impact factor: 2.571

2.  Surgical undertreatment of glaucoma in black beneficiaries of medicare.

Authors:  U Devgan; F Yu; E Kim; A L Coleman
Journal:  Arch Ophthalmol       Date:  2000-02

3.  Sutureless, posterior lamellar keratoplasty: a case report of a modified technique.

Authors:  Gerrit R J Melles; Frank Lander; Carla Nieuwendaal
Journal:  Cornea       Date:  2002-04       Impact factor: 2.651

4.  Trends in the indications for penetrating keratoplasty in the midwestern United States.

Authors:  K R Dobbins; F W Price; W E Whitson
Journal:  Cornea       Date:  2000-11       Impact factor: 2.651

5.  Lesson from Canada's Universal Care: socially disadvantaged patients use more health services, still have poorer health.

Authors:  David A Alter; Therese Stukel; Alice Chong; David Henry
Journal:  Health Aff (Millwood)       Date:  2011-02       Impact factor: 6.301

6.  Deep lamellar endothelial keratoplasty in the first United States patients: early clinical results.

Authors:  M A Terry; P J Ousley
Journal:  Cornea       Date:  2001-04       Impact factor: 2.651

7.  Gender and blindness: a meta-analysis of population-based prevalence surveys.

Authors:  I Abou-Gareeb; S Lewallen; K Bassett; P Courtright
Journal:  Ophthalmic Epidemiol       Date:  2001-02       Impact factor: 1.648

8.  Changing indications for penetrating keratoplasty in Greece, 1982-2006: a multicenter study.

Authors:  Charalambos S Siganos; Nikolaos S Tsiklis; Dimitrios G Miltsakakis; Nikolaos S Georgiadis; Irene N Georgiadou; George D Kymionis; Ioannis G Pallikaris
Journal:  Cornea       Date:  2010-04       Impact factor: 2.651

9.  A technique to excise the descemet membrane from a recipient cornea (descemetorhexis).

Authors:  Gerrit R J Melles; Robert H J Wijdh; Carla P Nieuwendaal
Journal:  Cornea       Date:  2004-04       Impact factor: 2.651

10.  National outcomes of penetrating keratoplasty. Risks of endophthalmitis and retinal detachment.

Authors:  L P Aiello; J C Javitt; J K Canner
Journal:  Arch Ophthalmol       Date:  1993-04
View more
  5 in total

1.  Trends in Corneal Transplantation in Keratoconus.

Authors:  Daniel Sarezky; Stephen E Orlin; Wei Pan; Brian L VanderBeek
Journal:  Cornea       Date:  2017-02       Impact factor: 2.651

2.  Changing trends in corneal graft surgery: a ten-year review.

Authors:  Ugo de Sanctis; Camilla Alovisi; Luigi Bauchiero; Guido Caramello; Gianfranco Girotto; Claudio Panico; Luisa Vinai; Federico Genzano; Antonio Amoroso; Federico Grignolo
Journal:  Int J Ophthalmol       Date:  2016-01-18       Impact factor: 1.779

3.  A Novel Approach of Harvesting Viable Single Cells from Donor Corneal Endothelium for Cell-Injection Therapy.

Authors:  Hon Shing Ong; Gary Peh; Dawn Jin Hui Neo; Heng-Pei Ang; Khadijah Adnan; Chan Lwin Nyein; Fernando Morales-Wong; Maninder Bhogal; Viridiana Kocaba; Jodhbir S Mehta
Journal:  Cells       Date:  2020-06-09       Impact factor: 6.600

Review 4.  Evolution of therapies for the corneal endothelium: past, present and future approaches.

Authors:  Hon Shing Ong; Marcus Ang; Jodhbir Mehta
Journal:  Br J Ophthalmol       Date:  2020-07-24       Impact factor: 4.638

5.  Corneal Endothelial Cell Migration and Proliferation Enhanced by Rho Kinase (ROCK) Inhibitors in In Vitro and In Vivo Models.

Authors:  Landon C Meekins; Noel Rosado-Adames; Rupalatha Maddala; Jiagang J Zhao; Ponugoti V Rao; Natalie A Afshari
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-12-01       Impact factor: 4.799

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.